SUPN Q1 2017 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$58M+33.7% YoY

Gross Profit

$55M94.9% margin

Operating Income

$17M29.2% margin

Net Income

$10M17.9% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

-7.7%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$322M

Total Liabilities

$116M

Stockholders' Equity

$206M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$43M	+33.7%
Gross Profit	$55M	$41M	+33.1%
Operating Income	$17M	$5M	+215.7%
Net Income	$10M	$5M	+113.4%